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LATE BREAKING CLINICAL TRIALS
Results From Late Breaking Clinical Trials Sessions at ACC ’97
ROBERT J. CODY, MD, FACC
Columbus, Ohio
The following are summaries of the principal investigator
presentation of clinical trial results presented at the “Late
Breaking Trials” symposia during the 46th Annual Scientific
Session of the American College of Cardiology, held March
16–19, in Anaheim, California. For each trial, physician com-
mentary is provided by Robert J. Cody, MD, FACC. As
co-chair of the Scientific Session, Dr. Cody was responsible for
the assembly of these symposia.
Late Breaking Clinical Trials I
Global Use of Strategies to Open Coronary Arteries
Trial (GUSTO III)
ERIC J. TOPOL, MD, FACC
CLEVELAND CLINIC FOUNDATION, CLEVELAND, OHIO
This trial compares two different plasminogen activators: t-PA
(alteplase) and a mutant form of t-PA known as r-PA (rete-
plase). The primary hypothesis was that reteplase would be
superior to alteplase in reducing mortality in acute myocardial
infarction at 30 days.
This is the primary end point: At 30 days, the mortality rate
in the r-PA group was 7.43%, and with t-PA it was 7.22%. The
rate of hemorrhagic strokes was very close: 0.91% for r-PA
versus 0.88% for t-PA. The overall stroke rate was 1.67 for
r-PA versus 1.83 for t-PA. The rate of bleeding events was
remarkably close between the two treatments.
The Steering Committee deliberated over 2 days and very
carefully selected this conclusion: In this trial of .15,000
patients, r-PA did not significantly reduce 30-day mortality
compared with t-PA. This was the primary end point of the
trial. No statistical difference was observed in stroke or death
or nonfatal disabling stroke for r-PA versus t-PA. With 95%
confidence, it cannot be excluded that absolute mortality for
t-PA is 1.1% better than r-PA or that r-PA is 0.7% better than
t-PA. There is still some uncertainty as to whether these drugs
can be regarded as equivalent.
The choice of treatment will depend on further analysis of
these data with more extended follow-up, cost of the drug, ease
of use and other issues. This is the first trial of a third-
generation, bioengineered t-PA mutant, and the question that
is left to answer is, can we beat “Mother Nature”?
Commentary. The primary hypothesis, that reteplase
would be superior to alteplase in reducing mortality in acute
myocardial infarction at 30 days, was rather bold, given the well
established clinical outcome with alteplase in previous trials.
The cautionary comments of Dr. Topol regarding the deliber-
ations of the Steering Committee not withstanding, this mul-
tinational trial of .15,000 patients demonstrates outcome
equivalence for these two modes of therapy. Cost of drug, ease
of use, etc., are important factors that do not weaken the
primary finding of equivalence.
The Argatroban in Myocardial Infarction
Trial (AMI)
PIERRE THEROUX, MD, FACC
MONTREAL HEART INSTITUTE, MONTREAL, QUEBEC, CANADA
The AMI trial was a Phase II, randomized, double-blind,
placebo-controlled study of argatroban adjunctive treatment to
streptokinase. Argatroban is a direct thrombin inhibitor.
Patients with acute myocardial infarction (MI) were ran-
domized to low or medium dose argatroban or placebo. All 910
of the patients received streptokinase.
There were no statistically significant differences at 30 days
in the composite clinical end point, consisting of death; shock
or congestive heart failure; or recurrent MI. The rates were
16.1% in the placebo group, 19.9% in the low dose argatroban
group and 18.8% in the high dose argatroban group. There
were no significant differences between the individual compo-
nents of the composite end point. However, in the subset of
patients treated within 3 h after the onset of chest pain,
significant risk reduction with the high dose of argatroban was
observed.
The safety profile of the drug was excellent. Major bleeding
was not increased.
In conclusion, in this dose-ranging Phase II study, argatro-
ban was very safe, but was not associated with benefit in the
composite end point or in the individual components of the
composite end point. Of course, this trial was not powered to
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detect a statistically significant benefit. Nevertheless, a favor-
able trend could be observed to benefit when treatment was
applied early, within 3 h after the onset of symptoms.
Commentary. The authors tested the premise that argatro-
ban, a direct thrombin inhibitor, would provide additional
benefit to streptokinase in acute MI. The absence of demonstra-
ble benefit in the argatroban–streptokinase, compared with the
placebo–streptokinase group, is discouraging. As a dose-
ranging/safety trial, it was not powered to determine differ-
ences for components of the primary end points, particularly
death. Nonetheless, the absence of more clear-cut trends for
argatroban benefit suggest 1) that the rationale for com-
bined adjunctive therapy is not valid; 2) that the magnitude
of additional benefit with argatroban is too small for
detection in such a trial design; 3) that the time to end point
was not targeted or matched to the time of optimal clinical
benefit that can be achieved by this combination. Close
scrutiny of study design may be required before future
studies of the direct thrombin inhibitors.
Platelet Receptor Inhibition for Ischemic Syndrome
Management (PRISM)
HARVEY D. WHITE, DSC, FACC
GREEN LANE HOSPITAL, AUCKLAND, NEW ZEALAND
Tirofiban is a small, nonpeptide drug that blocks the platelet
glycoprotein (GP) IIb/IIIa receptor, which is the final common
pathway for the aggregation of platelets with fibrinogen. It has
a rapid onset of action and rapid reversal of effect after drug
discontinuation.
Finding the effect of a 48-h infusion of tirofiban compared
directly with heparin in patients with ischemic syndromes was
the intent of the study. Patients were randomized to either
tirofiban or heparin using a double-blind design. Heparin was
received by 1,616 patients; tirofiban by 1,615.
The composite end point was the incidence of death, new
myocardial infarction or refractory ischemia. At 48 h, the
composite end point was reduced from 5.9% in the heparin
group to 3.8% in the tirofiban group. That is a 37% reduction,
with a p value of 0.007. At 30 days, death was reduced from
3.6% to 2.3%, for a 39% reduction, with p 5 0.02. The 95%
confidence limits ranged from a 60% reduction to an 8%
reduction.
In this first large trial comparing a IIb/IIIa receptor antag-
onist with heparin, tirofiban was well tolerated and highly
effective at reducing acute ischemic events.
Commentary. Variability of heparin levels and activity has
always been a potential risk and cause for concern in acute or
unstable ischemic syndromes. This study indicates that tirofi-
ban provides a new approach to the management of these
patients. Tirofiban was not only superior to heparin at the 48-h
primary composite end point; it also provided an unequivocal
mortality reduction at 30 days after onset of therapy, indicating
an unexpected longer term benefit. Despite the longer term
benefit, emphasis on the logical short-term attenuation of
acute ischemic syndromes should remain the emphasis of
comparative studies with heparin. Can tirofiban replace hepa-
rin in future clinical practice? Will the benefit of a low weight,
nonpeptide drug pave the way for oral agents in this class of
therapy?
Platelet Receptor Inhibition for Ischemic Syndrome
Management in Patients Limited by Unstable Signs
and Symptoms (PRISM-PLUS)
PIERRE THEROUX, MD, FACC
MONTREAL HEART INSTITUTE, MONTREAL, QUEBEC, CANADA
High risk patients with unstable angina and non-Q wave
myocardial infarction (MI) were enrolled in the study. The
goal was to test tirofiban in the context of a global and
comprehensive management strategy of unstable angina, in-
cluding aspirin, heparin and the use of coronary interventions
whenever indicated.
The primary end point of the trial was a composite of death,
MI and refractory ischemia at 7 days after randomization.
Heparin plus an infusion of tirofiban that lasted at least 48 h
was received by 773 patients. Heparin alone was received by
797 patients.
At 7 days, tirofiban treatment caused a significant reduction
in the composite end point, from 17.9% to 12.9%, for a 34%
reduction, with a significant p value of 0.004. There was a 32%
reduction in refractory ischemia and a 47% reduction in the
risk of MI.
At 30 days, the benefits were sustained. There was a
significant 23% reduction in the composite end point. A trend
was observed toward more bleeding in the tirofiban group, with
major bleeding occurring in 1.8% of the tirofiban group and
1.2% of the heparin group. Treatment was discontinued due to
bleeding in 3.5% of the tirofiban group and 1.1% of the
heparin group.
Commentary. The evaluation of higher risk patients in
PRISM-PLUS distinguishes this study from PRISM. Subgroup
analysis of the outcome in the non-Q wave MI group will be
particularly interesting, in view of the VANQWISH trial,
summarized elsewhere in these highlights. The higher risk
patient population in this trial facilitated the potential for both
benefit and risk in the tirofiban–heparin group. The observed
benefit for the primary end point at both 7 and 30 days is
supplemented and confirmed by the tirofiban versus heparin
design of PRISM. The observed risk for increased bleeding in
the tirofiban–heparin group suggests that these agents should
not be combined in future trials, and PRISM suggests that the
study design of tirofiban versus heparin is warranted and will
minimize the risk of bleeding.
2 CODY JACC Vol. 30, No. 1
RESULTS FROM LATE BREAKING CLINICAL TRIALS July 1997:1–7
Late Breaking Clinical Trials II
Organization to Assess Strategies for Ischemic
Syndromes (OASIS Registry)
SALIM YUSUF, MBBS, PHD, FACC
HAMILTON GENERAL HOSPITAL, HAMILTON, ONTARIO, CANADA
OASIS is a prospective registry of 8,000 patients with acute
myocardial ischemia without ST segment elevation. The study
was done in Brazil, the United States, Canada, Australia,
Hungary and Poland.
The primary focus of this presentation is to show the data
related to the patterns of practice regarding invasive strategy
across these countries. There is a wide range of patterns of
practice for angiography. Before discharge, 70% of patients in
Brazil and 60% of those in the United States had an angio-
gram. Contrast this with Hungary and Poland, where it is 20%
and 7%, with intermediate numbers for Canada and Australia.
The gradient for percutaneous transluminal coronary angio-
plasty (PTCA) and coronary artery bypass graft surgery
(CABG) is even more marked.
When the two countries with the highest rates were com-
bined and compared with an aggregate of the other countries,
the in-hospital angiography rate was 58% versus 20%. PTCA
was three times higher, and the CABG rate was seven times
higher, in Brazil and the United States versus the other
countries. However, for death and myocardial infarction (MI)
at 7 days, the rates were similar: 4.6% in the United States and
Brazil versus 4.9% in the other countries.
In contrast, refractory angina was 30% lower in the United
States and Brazil than in the countries with more conservative
management. Disturbingly, the stroke rate was threefold
higher in the countries with the more aggressive management.
The incidence of major bleeding requiring transfusion was also
2.7-fold higher in the countries with more aggressive manage-
ment.
At the end of 6 months, the differential in intervention rates
narrows but is still there. There is no significant difference in
death or MI. As before, refractory angina was reduced by 30%
in the countries with the more invasive strategy, and that
difference is highly significant. The same difference in strokes
persists.
Although this is not a randomized, controlled trial, the
OASIS Registry suggests that a policy of routine early and
aggressive invasive strategy may not be preferable to a more
conservative strategy of delayed and selective angiography.
Commentary. This study suffers from the limitations noted;
however, a controlled, randomized trial across such diverse
countries would be quite difficult. This study does not provide
information regarding access to medical care, so that the social
and political factors influencing hospital admission potentially
confound the observations.
Veterans Affairs Non–Q Wave Infarction Strategies
In-Hospital (VANQWISH)
WILLIAM E. BODEN, MD, FACC
VETERANS AFFAIRS MEDICAL CENTER, SYRACUSE, NEW YORK
It is clear that the management of patients with a non–Q wave
myocardial infarction (MI) has become increasingly more
aggressive during the past decade. The objective of the
VANQWISH trial was to compare early and late clinical
outcomes in patients with a non–Q wave who were randomized
either to an early invasive strategy, defined as coronary angiog-
raphy followed by myocardial revascularization as dictated by
coronary anatomic findings, versus an early conservative strat-
egy, which entailed the performance of a radionuclide ven-
triculogram followed by a predischarge thallium stress test.
All patients admitted to 15 Veterans Affairs medical centers
from April 1993 to December 31, 1995 with suspected acute
MI were screened for possible randomization. Nine hundred
twenty patients were enrolled.
At the time of discharge, there were 21 deaths in the
invasive arm compared with 6 in the conservative arm, a
significant difference. After discharge, there were 59 deaths
versus 53 deaths, which was not significantly different. The
average length of stay was 9.5 days in the invasive strategy and
8.2 days in the conservative strategy, a highly significant
difference.
An initial conservative management strategy should be
adopted to stabilize patients with a non–Q wave MI, after
which invasive procedures should be utilized electively and
selectively.
Commentary. Many physicians would indicate that the
observations in this well controlled study simply reiterate the
tenants of good clinical practice and therefore tell us “nothing
new.” However, this would be a cursory criticism. The evolu-
tion of aggressive cardiovascular management over the past
decade has blurred discrimination of patient populations and
procedural methods to identify the high risk group and the
outcome of the special populations, such as the non–Q wave
MI population. This trial provides compelling evidence to
support “good clinical practice” and guidelines for the man-
agement of a very large and important subgroup of acute MI in
an era of almost routine aggressive intervention.
Montreal Heart Attack Readjustment
Trial (M-HART)
NANCY FRASURE-SMITH, MD
MONTREAL HEART INSTITUTE, MONTREAL, QUEBEC, CANADA
Psychological and social factors have an impact on prognosis
after heart attack. M-HART addressed the question of
whether a nursing intervention program aimed at lowering
psychological distress would have an impact on cardiac mor-
tality in women and men after a heart attack.
Patients were contacted by phone monthly for 1 year and
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responded to a standardized measure of psychological distress.
Any patient who reported high levels of distress during that
phone call then received repeated interventions from a nurse
with cardiac experience.
The study design was a randomized, clinical trial with 903
men and 473 women assigned either to the M-HART treat-
ment program of monthly phoning and nurse visits or to usual
care with no calls and no nursing visits. The enrollment target
was met for men, but only two-thirds of the target for women
was achieved; 81% of the men in the treatment group and 86%
of the women received nursing visits, which took place in
patients’ homes.
The results for men: This enormous amount of nursing care
made no difference to their survival. The results for women:
There was a doubling of risk of cardiac mortality associated
with treatment, and it was marginally significant at p 5 0.069.
The confidence intervals show that there was no small possi-
bility that the treatment had a beneficial effect for women and
that there was a substantial possibility of a harmful impact.
It is important to point out that a specific program, not a
profession was evaluated. Even the most seemingly innocuous
intervention by the most well meaning professional may have
harmful effects for some patients.
Commentary. This is a trial with a surprising outcome: On
the surface of the results/interpretation, intervention by health
care professionals (in this case nurses), attempting to reduce
stressful events after myocardial infarction, may actually in-
crease the risk of death. The conclusions drawn from this study
may be numerous and purely interpretive. However, the in-
creased risk of mortality in women well represents a remark-
able observation that cannot be dismissed by superficial and
whimsical interpretation. How would one carry this observa-
tion to a second trial, or extend the observation to a larger
population? Hopefully, a rational explanation will evolve from
a more detailed review of the M-HART database.
Ibutilide for Post-Cardiac Surgery AF Termination
PETER R. KOWEY, MD, FACC
LANKENAU HOSPITAL, WYNNEWOOD, PENNSYLVANIA
Atrial arrhythmias after cardiac surgery cause significant mor-
bidity. Despite the use of beta-adrenergic blocking agents and
a variety of other drugs, the incidence of atrial arrhythmia after
cardiac surgery remains at ;15% to 40%.
The objective of this study was to determine the efficacy and
safety of ibutilide for the acute termination of atrial fibrillation
or atrial flutter after cardiac surgery. Of the 302 patients,
two-thirds had atrial fibrillation and one-third had atrial flut-
ter.
This was a placebo-controlled, parallel dose group study. In
the placebo group there was a 15% rate of restoration of
normal sinus rhythm. This rose to 40% in the 0.25-mg dose of
ibutilide, 47% in the 0.5-mg dose and 57% in the 1.0-mg dose.
The mean time to arrhythmia termination in this study was
;30 min.
Patients with atrial flutter had a much higher efficacy,
approaching 80% for the 1.0-mg dose. Patients with atrial
fibrillation had a 45% success rate with the 1.0-mg dose; 9.6%
of the patients who received ibutilide had a ventricular arrhyth-
mia compared with 1.2% of patients who received placebo.
There was less than a 2% incidence of torsade de pointes.
Ibutilide represents a useful alternative therapy for the
treatment of atrial arrhythmia after cardiac surgery.
Commentary. These results provide optimism for the use
of ibutilide after cardiac surgery, where the occurrence of atrial
arrhythmias is quite common and often difficult to manage in
the recuperating patient. A clear advantage over beta-blockade
would be in the patient with poor ventricular function and
those with chronic lung disease, which includes a large propor-
tion of these patients. The observation of increased ventricular
arrhythmias with ibutilide is disturbing, particularly in this
population, where fluid and electrolyte abnormalities or ongo-
ing ischemia may be present. Thus, while encouraging, antiar-
rhythmic agents that solve one problem continue to be associ-
ated with the induction of additional problems.
Evaluation of Losartan in the Elderly
Trial (ELITE)
BERTRAM PITT, MD, FACC
UNIVERSITY OF MICHIGAN, ANN ARBOR, MICHIGAN
This trial took patients who were angiotensin-converting en-
zyme (ACE) inhibitor naive and had New York Heart Asso-
ciation II to IV heart failure. Three hundred seventy patients
were randomized to the ACE inhibitor captopril and 352 to the
angiotensin II receptor antagonist losartan. Patients were
followed up for 48 weeks.
The primary end point of the trial was an increase in serum
creatinine $0.3 mg/dl. In the primary end point, there was no
difference between the two groups. In fact, the incidence of
renal dysfunction in this group of elderly patients was quite
low, ;10.5% in each group. However, losartan was signifi-
cantly better tolerated than captopril. This was highly signifi-
cant and related to ACE inhibitor-induced side effects such as
cough.
As the incidence of total mortality was examined, there was
a significant difference favoring losartan. There was a 46%
reduction in all-cause mortality in patients randomized to
receive losartan (p 5 .035).
Commentary. This is the first large-scale trial prospectively
designed to evaluate the treatment of systolic left ventricular
dysfunction in the elderly. In addition, this population had not
received an ACE inhibitor before randomization. Although no
difference in renal function was observed between treatment
groups (the primary end point, together with induced hyper-
kalemia), this elderly population tolerated losartan, with a
tendency for more hypotension, but much less cough than
captopril. However, one must avoid overinterpreting the im-
portance of death reduction in the losartan group. Mortality
4 CODY JACC Vol. 30, No. 1
RESULTS FROM LATE BREAKING CLINICAL TRIALS July 1997:1–7
was not a prespecified primary end point, and the study was not
powered to address mortality subgroups. Furthermore, the
number of mortal events was quite small, despite the risk
reduction for all-cause mortality of 46%, greatly influenced by
the number of sudden deaths (5 of 352 patients with losartan,
14 of 370 patients with captopril). This article appeared in The
Lancet (349:747–752) at the time of ACC ’97 and has stimu-
lated a second larger trial to address the mortality issue.
Late Breaking Clinical Trials III
The Fluvastatin Angioplasty Restenosis
Trial (FLARE)
PATRICK W. SERRUYS, MD, FACC
ERASMUS UNIVERSITY, ROTTERDAM, THE NETHERLANDS
The objective of this trial was to compare the effect of
treatment with fluvastatin administered 2 weeks before and for
26 weeks after percutaneous transluminal coronary angioplasty
(PTCA). One thousand fifty-four patients were randomized.
In the treated group, at the time of PTCA there was a
decrease in low density lipoprotein cholesterol of 37%, which
was sustained at the level of 34% and at 33% at 1 month and
6 months, with no change in the placebo group.
The primary angiographic end point was the change in
minimal lumen diameter (MLD). At follow-up at 6 months, the
two curves are strictly superimposed, indicating that there is no
effect on the loss in MLD. In terms of clinical events, there was
one observation that is rather fascinating. The combined
incidence of death and myocardial infarction (MI) was 1.5% in
the fluvastatin group compared to 4% in the placebo group.
For the composite end point of death, MI, coronary artery
bypass graft surgery and repeat PTCA, at 9 months the two
curves are almost superimposed, with 92 patients in the
fluvastatin group versus 99 in the placebo group reaching an
end point.
In conclusion, treatment with fluvastatin does not affect the
process of restenosis and is thus not indicated for this purpose.
However, the beneficial clinical effect on mortality and MI was
remarkable in this medium-sized trial. This has not been
previously reported, and warrants further investigation in a
larger trial.
Commentary. This study demonstrates that lipid reduction
preparatory to and immediately after PTCA does not alter the
occurrence of angiographically determined restenosis or the
primary composite end point. As with the ELITE Trial, an
unexpected mortality reduction, in a trial that was not designed
to look for mortality differences, is intriguing. However, this
can only be interpreted as “hypothesis generating” at this point
and, perhaps, the basis for a more detailed prospective trial.
However, if we already know that lipid reduction by the
HMG-CoA reductase group improves mortality (4S Trial and
others), can we be really surprised by these observations?
Study to Determine Rotablator and Transluminal
Angioplasty Strategy Trial (STRATAS)
PATRICK L. WHITLOW, MD, FACC
CLEVELAND CLINIC, CLEVELAND, OHIO
Of all the interventional devices, the Rotablator has the unique
potential to specifically enlarge the coronary lumen without
causing deep wall damage, thereby theoretically minimizing
restenosis. In STRATAS, the hypothesis was tested that rou-
tine percutaneous transluminal coronary angioplasty (PTCA)
after rotational atherectomy results in a smaller lumen than
after Rotablator alone at 6-month angiographic follow-up.
STRATAS was a 500-patient trial with 250 patients random-
ized to each strategy.
The reference lumen diameter was 2.4 mm in both groups.
The postprocedural MLD was 1.8 versus 1.78 mm: exactly the
same. All quantitative coronary angiographic analysis was
statistically indistinguishable between groups. Angiographic
success was 93% for both strategies. Major complications
occurred in 3.6% of the routine treatment group and in 2% of
the aggressive treatment group.
One of the potential complications with rotational atherec-
tomy is angiographically detectable slow flow. The incidence of
slow flow doubled in the aggressive treatment group: 15%
versus 7.3%. However, in most cases, the slow flow was
transient. Unresolved slow flow occurred in only three patients
in the study (0.6%), all in the aggressive treatment group.
At 6 months, death occurred in 4% of the routine
strategy group and in 1.6% of the aggressive strategy group.
Myocardial infarction was infrequent: 0.8% for the routine
strategy versus 2% for the aggressive strategy; bypass sur-
gery was required in 3.6% versus 1.6% and percutaneous
revascularization procedures in 20% versus 24.9%, respec-
tively. There were no statistical differences between the two
strategies at 6 months.
Commentary. Analysis of this study is ongoing, and firm
conclusions regarding the risk/benefits of primary Rotablator
atherectomy in this population await this subsequent analysis,
particularly in terms of clinical outcome.
Intravenous nPA for Treating Infarcting
Myocardium Early (InTIME)
PETER DEN HEIJER, MD
UNIVERSITY HOSPITAL GRONINGEN, GRONINGEN,
THE NETHERLANDS
Novel plasminogen activator, or n-PA (lanoteplase), is a
genetically engineered variant of tissue-type plasminogen ac-
tivator (t-PA). It has a longer plasma half-life than t-PA,
making it suitable for single bolus administration.
InTIME was a multicenter, randomized, double-blind,
double-dummy, parallel-design dose-finding study. Four differ-
ent weight-adjusted doses of n-PA were compared with a
control group who received accelerated t-PA.
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There was a clear dose-response relation, ranging from a
24% Thrombolysis in Myocardial Infarction (TIMI) grade 3
flow rate at 60 min for the lowest dose to 47% for the
highest dose. At 90 min, the rates were 26% for the lowest
dose and 57% for the highest dose. At 90 min, the TIMI
grade 3 flow rate was 46% in the t-PA group, which was not
significantly different than at the high dose of n-PA. But at
90 min, the rate of TIMI grade 2 and 3 flow taken together
was 83% in the n-PA group versus 71% in the t-PA group,
a significant difference.
The incidence of moderate and major bleeding was low,
comparable to t-PA; full efficacy and safety will be addressed in
a large mortality study.
Commentary. n-PA enters the retaplase versus alteplase
confrontation! As indicated in the Commentary for the
GUSTO III Trial, improved pharmacodynamics, drug dura-
tion and cost and risk of bleeding have become predominant
issues in the thrombolytic arena, in follow-up to well
documented efficacy. As demonstrated by InTIME, the
n-PA results indicate that this longer acting compound, with
documented coronary flow efficacy and lower bleeding risk,
is an important contender and worthy of additional large-
scale mortality trials (and direct comparison with the other
compounds in this class?).
Transmyocardial Laser Revascularization Versus
Medical Management in Patients Unamenable to
Conventional Revascularization
JAMES E. LOWE, MD, FACC
DUKE UNIVERSITY, DURHAM, NORTH CAROLINA
The purpose of this study was to determine whether transmyo-
cardial laser revascularization (TMR) provided any clinical or
functional benefits compared with optimal medical manage-
ment in patients with Canadian Cardiovascular Society (CCS)
class 3 or 4 angina who are refractory to medical therapy but
who are not candidates for either percutaneous transluminal
coronary angioplasty (PTCA) or primary or secondary coro-
nary artery bypass graft surgery (CABG).
Ninety-seven patients were randomized to TMR therapy
and 101 to continued maximal medical therapy. Defining
success as a decrease of at least two angina classes, the overall
success rate in the TMR group is 70%. There was essentially
no improvement at all in the medical group.
According to the author, the crossover group is the most
fascinating group and generated the most important piece of
data to result from this study. Patients in the medical group
were allowed to cross over to TMR after 6 months of contin-
ued medical therapy. There is a 39% crossover rate at 6
months, which shows the failure of optimal medical manage-
ment. In patients who crossed over and received TMR in the
setting of ongoing unstable angina, the combined operative
mortality is totally unacceptable at 20%.
TMR should be considered for patients with CCS class 3
or 4 angina who have been turned down for PTCA and
operation but should not be considered for patients with
unstable angina.
Commentary. Although these results are quite interesting,
TMR should probably be considered for additional study
rather than offered as accepted therapy in this high risk class.
All physicians have patients with severe angina, not considered
candidates for PTCA/CABG. However, the definition of “re-
fractory to medical therapy” is subject to interpretation, as is
the need for crossover to a procedure when crossover cannot
occur from surgery to medicine, strictly speaking. Larger
numbers of patients in randomized trials are warranted be-
cause a true placebo group (thoracotomy, no laser treatment)
cannot be evaluated.
Beta-Energy Restenosis Trial (BERT I)
SPENCER B. KING III, MD, FACC
EMORY UNIVERSITY, ATLANTA, GEORGIA
Low dose intravascular radiation has been applied in experi-
mental models of restenosis. The objective of this study was to
evaluate a system designed to use beta-radiation. Beta-
radiation has its maximal effect within a few millimeters of the
source, without scatter and without penetration to other
sensitive tissues of the body or catheter laboratory personnel.
Eighteen patients have received angiographic follow-up.
There have been three reinterventions in 6 months. At the time
of angioplasty, the percent narrowing was 73%. After angio-
plasty it was 24%, and at final follow-up it was 28%. The
minimal lumen diameter was 0.78 mm before treatment,
2.17 mm at the end of the procedure and 2.07 mm at follow-up,
for a late loss index of only 5%.
On the basis of these encouraging findings, intravascular
beta-radiation may be an important therapy for reducing
restenosis. A large randomized trial is soon to begin.
Commentary. Some clinical trials must take the form of
“promissory note,” rather than final outcome, when the pre-
scribed treatment is more radical or revolutionary than others.
Radiation-induced attenuation of restenosis has potential im-
portance as the incidence of post-stent restenosis increases.
One can only hope that the results of the large randomized
trial will be available for these late breaking trials within the
near future; these pilot results, particularly with the small late
loss index, are encouraging.
Barath Cutting Balloon Global
Randomized Trial
RAOUL BONAN, MD, FACC
MONTREAL HEART INSTITUTE, MONTREAL, QUEBEC, CANADA
The objective of this multicenter, randomized study was to
evaluate the acute and long-term effect of the cutting
balloon (CB) to dilate human coronary arteries. The prin-
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ciple of the cutting balloon is to cut and dilate with a single
short inflation, to reduce the trauma of conventional percu-
taneous transluminal coronary angioplasty (PTCA), which
uses high pressure multiple inflations and creates substantial
wall damage.
The trial enrolled 1,245 patients. This report included 1,028
patients with 1,074 lesions. The overall success rate (including
MACE and non-Q MI) was 85% for the CB and 87% for
PTCA, which is similar to other large studies. When the end
points of death, emergency coronary artery bypass graft sur-
gery, Q wave myocardial infarction and all other reclosures
were combined, there is a 5% event rate for the cutting balloon
and a 3.7% rate for the PTCA group. If the use of adjunct
devices like stents are then added, the results are, 11.2% for
the cutting balloon group and 13.6% for the PTCA group.
Neither of these reaches significance.
The dilation parameter differences between cutting balloon
and PTCA are as hypothesized. The mean inflation pressure
for cutting balloon was 7.1 atm, with a shorter inflation time at
84 s versus 9.6 atm and 145 s for PTCA. At p 5 0.001, the
difference was significant.
The acute clinical results were identical in the two groups.
Besides perforation (CB 5 1.3% vs. PTCA 5 0), there was no
difference in acute complications or abrupt vessel closure. The
restenosis rate will be presented in late summer at the Euro-
pean Society of Cardiology meeting, since the last patient was
enrolled on November 25, 1996, and no interim analyses will be
allowed by the study rules.
Commentary. On the basis of the results provided for this
late breaking trial session, there are no apparent clinical
benefits of the cutting balloon compared with the standard
balloon. The risk of perforation with the cutting balloon may
be no better than the risks associated with the additional
2.5 atm and 61 s of the standard balloon. Is it sufficient for
a new technology to be just as good, or should we expect the
new technology to be better?
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